Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics of thiazolidinedione therapy.

Pharmacogenomics - 1 Aug 2007

Aquilante Christina L

Abstract excerpt

The thiazolidinediones (TZDs) are peroxisome proliferator-activated receptor-gamma agonists and have glucose-lowering, insulin-sensitizing and anti-inflammatory effects. TZDs are approved for the treatment of Type 2 diabetes, and have been studied as a diabetes-prevention strategy. Despite widespread use of TZDs, a large number of patients fail to achieve a substantial reduction in glucose, or an improvement in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Diabetes Mellitus, Type 2
Share to Genetic Variation
Share to Insulin Resistance

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pharmacogenetics

Share to Thiazolidinediones

Source

Identifiers

PMID: 17716227
DOI: 10.2217/14622416.8.8.917

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics of thiazolidinedione therapy.PMID 17716227Read ↗

Pharmacogenomics and Pharmacogenetics of Thiazolidinediones: Role in Diabetes and Cardiovascular Risk FactorsSemantic proximity Read ↗

Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicineSemantic proximity Read ↗

Pharmacogenetic studies update in type 2 diabetes mellitusSemantic proximity Read ↗

Pharmacogenomics in type 2 diabetes: oral antidiabetic drugs.Semantic proximity Read ↗

Current Progress in Pharmacogenetics of Second-Line Antidiabetic Medications: Towards Precision Medicine for Type 2 DiabetesSemantic proximity Read ↗

The role of pharmacogenetics in drug disposition and response of oral glucose-lowering drugs.Semantic proximity Read ↗

Pharmacogenetics of Type 2 Diabetes—Progress and ProspectsSemantic proximity Read ↗

Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphismsSemantic proximity Read ↗

An Update on the Pharmacogenomics of Metformin: Progress, Problems and PotentialSemantic proximity Read ↗

Current progress in pharmacogenomics of Type 2 diabetes: A systemic overview.Semantic proximity Read ↗

Pharmacogenetics and personalized treatment of type 2 diabetesSemantic proximity Read ↗

Sequence variation in PPARG may underlie differential response to troglitazone.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.